Elevated intracellular cAMP levels generated by PDE4 inhibitors lead to downregulation of the inflammatory response by modulating the expression of NF-κB, TNF-α, IL-1β, IL-17, and other pro-inflammatory molecules found to be released in the mucosa of patients with IBD. This evidence concerns the gene PDE4A and inflammatory bowel disease.